However, our study revealed increased LSD1 expression in MM patients who experienced disease relapse after bortezomib regimen therapy, suggesting a potential role for LSD1 in mediating drug resistance through epigenetic reprogramming. The gene discussed is KDM1A; the disease is Miyoshi myopathy.